About This Episode
Today we’re joined by Kim Branson, the SVP and global head of artificial intelligence and machine learning at GSK.
We cover a lot of ground in our conversation, starting with a breakdown of GSK’s core pharmaceutical business, and how ML/AI fits into that equation, use cases that appear using genetics data as a data source, including sequential learning for drug discovery. We also explore the 500 billion node knowledge graph Kim’s team built to mine scientific literature, and their “AI Hub”, the ML/AI infrastructure team that handles all tooling and engineering problems within their organization. Finally, we explore their recent cancer research collaboration with King’s College, which is tasked with understanding the individualized needs of high- and low-risk cancer patients using ML/AI amongst other technologies.
Watch on Youtube
Connect with Kim!
- Article: Combining genetics and tech to double success rates for patients
- Article: Declaring War on Infectious Diseases
- Article: Could Tech be the right medicine for pharma R&D?
- Article: How to automate “the boring” in drug discovery
- Article: 23andMe to Use DNA Tests to Make Cancer Drugs
- Predictive Disease Modeling at 23andMe with Subarna Sinha – Episode #436
- Machine Learning: A New Approach to Drug Discovery with Daphne Koller – Episode #332